
Allergan acquires neurotoxin start-up Bonti for $195mm
Executive Summary
Allergan PLC agreed to buy private biotech Bonti Inc., which is developing botulinum neurotoxin serotype E (BoNT/E)-derived candidates.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com